rademikibart
·Code: CBP-201
rademikibart: developed by 1 company · 1 clinical trial tracked.
rademikibart evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect rademikibart to CNTB; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could rademikibart → CNTB affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Asthma Acute
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Connect Biopharma Holdings Ltd (CNTB) Asthma Acute | Phase 2 |
Clinical Trials (1)
A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation
Primary endpoint: Change from baseline in post-BD FEV1
Interventionalopen40 targetStarted 2026-08Completion 2027-012 sites · United StatesConnect Biopharm LLC
Frequently asked questions
Who is developing rademikibart?
rademikibart is being developed by Connect Biopharma Holdings Ltd.
How many clinical trials involve rademikibart?
BioSniper tracks 1 clinical trial involving rademikibart.